They also assessed plasma levels of high sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) and used these measures to reclassify men into high-risk (elevated hs-CRP and Lp-PLA2), moderate-risk (either elevated hs-CRP or Lp-PLA2), or low-risk (low hs-CRP and Lp-PLA2) groups. They have found that EndoPAT results are significantly lower in the high-risk group (1.3 +/- 0.04) compared to the moderate-risk (1.6 +/- 0.07, P < 0.05) and low-risk (2.0 +/- 0.1,P < 0.05) groups. According to binary logistic regression, EndoPAT result was a significant predictor of high risk status among men with CAD (P < 0.05). |
|
 |
